Market revenue in 2024 | USD 63.8 million |
Market revenue in 2030 | USD 123.8 million |
Growth rate | 11.7% (CAGR from 2025 to 2030) |
Largest segment | Exocrine |
Fastest growing segment | Endocrine |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Exocrine, Endocrine |
Key market players worldwide | Accuray Inc, AstraZeneca PLC ADR, Novartis AG ADR, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Ipsen Pharma, Eli Lilly and Co, Siemens Healthineers AG ADR, Elekta AB ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer treatment market will help companies and investors design strategic landscapes.
Exocrine was the largest segment with a revenue share of 88.4% in 2024. Horizon Databook has segmented the Spain pancreatic cancer treatment market based on exocrine, endocrine covering the revenue growth of each sub-segment from 2018 to 2030.
The pancreatic cancer treatment market in Spain is progressing steadily, driven by both the increasing incidence of pancreatic cancer and the growing number of patients opting for advanced therapies. The Spanish healthcare market benefits from a robust healthcare infrastructure and an increasing focus on oncology.
The market is primarily fueled by established treatments such as chemotherapy and targeted therapies, with notable contributions from companies such as Eli Lilly and Company, Roche, Novartis, and Pfizer, which are pivotal players in the region.
According to WHO, in 2022, pancreatic cancer was responsible for nearly 8,000 deaths in Spain, an increase from approximately 7,700 deaths in the previous year. Of these, 3,967 were men and 4,006 were women. Overall, the number of deaths attributed to pancreatic cancer was higher among men than women.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain pancreatic cancer treatment market , including forecasts for subscribers. This country databook contains high-level insights into Spain pancreatic cancer treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account